New Research trials at CODA

CODA research is excited to be participating in two new trials:

1. CODA research is recruiting for a study of an investigational medication for individuals with opioid dependence. We are looking for adults aged 18 – 65 years, who are dependent on opioids such as heroin, OxyContin, Vicodin, etc. Eligible volunteers will be provided with up to 8 months of no-cost intervention which includes an investigational medication for opioid dependence.
   1. Study lasts approximately 32 weeks
   2. This study includes a placebo; there is an 8 in 10 chance of receiving active medication and a 2 in 10 chance of receiving placebo (a substance that looks like the active medication but has no drug in it)
   3. Participation is voluntary, there will be no cost for participating, and participants will be compensated in retail gift cards,
   4. Possible risks and benefits of participation will be discussed with eligible participants in detail through a document called an informed consent.
   5. For more information about Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine please call CODA research at 503.231.6103 research@codainc.org. https://clinicaltrials.gov/ct2/show/NCT02357901?term=injectable+buprenorphine&rank=3
2. CODA research is recruiting for a detox study of individuals with opioid dependence. The study includes an inpatient stay in detox. We are looking for adult individuals over age 18, who would like to detox from opioids such as heroin, OxyContin, Vicodin, etc. Eligible volunteers will be provided with up to 14 days of no-cost intervention which includes a new non-opioid medication.
   1. Participation may last up to three weeks including screening and treatment
   2. There is a required inpatient treatment period in Tigard detox
   3. Participation is voluntary, there is no cost to participants, and participants will be compensated in retail gift cards
   4. Possible risks and benefits of participation will be discussed with participants in detail
   5. For more information about Open-Label, Safety Study of Lofexidine call CODA research at 503.231.6103 or research@codainc.org. https://clinicaltrials.gov/ct2/show/NCT02363998?term=lofexidine&rank=7